<DOC>
	<DOCNO>NCT02202603</DOCNO>
	<brief_summary>A Double blind ( oral ) , Open Label , Study Assess Safety , Pharmacokinetics Pharmacodynamics Oral PTH ( 1-34 ) healthy Subjects establish safety , tolerability , bioavailability , pharmacokinetic , pharmacodynamic profile Entera 's oral PTH ( 1 - 34 ) adult healthy human volunteer .</brief_summary>
	<brief_title>A Three Stage , Study Assess Safety , Pharmacokinetics Pharmacodynamics Oral PTH ( 1-34 ) Healthy Subjects</brief_title>
	<detailed_description>This study three stage . Stage 1 : Safety initial bioavailability Entera 's oral EP101 adult male healthy volunteer . ( SA-BA ) Stage 2 : Assessment bioavailability safety Entera 's oral EP101 adult male healthy volunteer . ( SA-BA-PK-PD ) Stage 3 : Safety , PK , PD final dose Entera 's oral PTH ( 1 - 34 ) adult healthy male female volunteer . ( SA-BA-PK-PD )</detailed_description>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>● Signed Informed consent study . Male female volunteer , age 18 50 year , BMI 1830 kg/m2 , inclusive , Subjects able adhere visit schedule protocol requirement Hematology , Chemistry Urinalysis value clinical significance reflect medical condition accord physician ' judgment might confound result study pose additional risk subject participation study . Hemoglobin level &gt; . 12.5 g/dl Blood pressure level clinical significance . Negative serology HIV , Hepatitis B , Hepatitis C. No know drug alcohol abuse Negative urinary drug abuse screen No allergy soy bean product . No prescription medication take within one month enrollment Overthecounter drug ( include vitamin ) take within 14 day prior visit 2 subject investigator ' discretion inclusion . No subject previous urolithiasis . Nonsmoking , In good health determine past medical history , physical examination , vital sign , electrocardiogram laboratory test screen ● Concurrent therapy , Investigator 's opinion , would interfere evaluation safety efficacy study medication . Treatment investigational product within last 30 day , enrollment intention enroll active study involve use investigational device drug . Presence condition circumstance , judgment Investigator , might increase risk patient decrease chance obtain satisfactory data achieve objective study . Active infection History drug alcohol abuse Known allergy sensitivities component study treatment study procedure , include Soy . Clinically diagnose psychiatric disorder may interfere patient study participation Medical history know suspected increase risk AEs relate study drug , investigator 's discretion Chronic illness , investigator 's discretion Female subject must negative serum pregnancy test screen willing able use medically acceptable method birth control ( nonhormonal intrauterine device condom , diaphragm condom , condom spermicide ) screen visit study termination visit declare abstain sexual intercourse screen visit study termination visit surgically sterile ( undergone bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) post menopausal . Postmenopausal woman define woman menstruation cessation 12 consecutive month prior sign inform consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>